Evanson Asset Management LLC Has $38,000 Position in Amarin Co. plc (NASDAQ:AMRN)

Evanson Asset Management LLC trimmed its position in Amarin Co. plc (NASDAQ:AMRN) by 55.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 59,878 shares of the biopharmaceutical company’s stock after selling 73,530 shares during the period. Evanson Asset Management LLC’s holdings in Amarin were worth $38,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of AMRN. Arkfeld Wealth Strategies L.L.C. bought a new stake in Amarin in the second quarter valued at approximately $28,000. Significant Wealth Partners LLC increased its position in shares of Amarin by 128.7% in the 1st quarter. Significant Wealth Partners LLC now owns 34,582 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 19,461 shares in the last quarter. Algert Global LLC acquired a new stake in Amarin during the 2nd quarter worth $34,000. Prospect Financial Services LLC bought a new position in Amarin during the second quarter worth about $41,000. Finally, China Universal Asset Management Co. Ltd. grew its stake in Amarin by 66.3% in the first quarter. China Universal Asset Management Co. Ltd. now owns 74,178 shares of the biopharmaceutical company’s stock valued at $66,000 after acquiring an additional 29,579 shares during the period. 22.25% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Amarin in a research report on Tuesday, June 18th. StockNews.com downgraded shares of Amarin from a “buy” rating to a “hold” rating in a report on Thursday, July 4th.

Insider Transactions at Amarin

In other news, CEO Aaron Berg bought 160,000 shares of the company’s stock in a transaction that occurred on Friday, August 2nd. The shares were acquired at an average price of $0.64 per share, with a total value of $102,400.00. Following the transaction, the chief executive officer now owns 805,380 shares in the company, valued at $515,443.20. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.96% of the stock is owned by insiders.

Amarin Trading Up 3.2 %

AMRN stock opened at $0.59 on Wednesday. The stock has a 50-day moving average price of $0.62 and a two-hundred day moving average price of $0.76. Amarin Co. plc has a 1 year low of $0.57 and a 1 year high of $1.37. The stock has a market cap of $244.31 million, a PE ratio of -4.96 and a beta of 1.92.

About Amarin

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.